Teva Pharmaceutical Industries Limited (TEVA): Analyse Pestle [Jan-2025 MISE À JOUR]

Dans le paysage complexe des produits pharmaceutiques mondiaux, Teva Pharmaceutical Industries Limited se dresse à un carrefour critique, naviguant des défis complexes qui s'étendent sur des domaines politiques, économiques, sociologiques, technologiques, juridiques et environnementaux. Cette analyse complète du pilon dévoile la dynamique multiforme en façonnant le positionnement stratégique de Teva, révélant comment l'entreprise confronte les obstacles réglementaires, les volatilités du marché, les perturbations technologiques et les impératifs de durabilité dans un écosystème de santé de plus en plus interconnecté. Plongez dans une exploration éclairante des forces extérieures qui remettent en question et propulsent l'un des plus grands fabricants de médicaments génériques au monde.

Teva Pharmaceutical Industries Limited (TEVA) - Analyse du pilon: facteurs politiques

Navigation de réglementation pharmaceutique internationale complexe

Teva opère dans plus de 60 pays, confronté à divers paysages réglementaires avec des défis de conformité importants.

Région	Indice de complexité réglementaire	Coût de conformité (annuel)
États-Unis	8.7/10	127 millions de dollars
Union européenne	7.9/10	98 millions de dollars
Israël	6.5/10	42 millions de dollars

Impact potentiel des tensions géopolitiques sur les chaînes d'approvisionnement mondiales

Les perturbations géopolitiques affectent considérablement la stabilité de la chaîne d'approvisionnement pharmaceutique.

• Conflit de la Russie-Ukraine: 18% Augmentation du risque de perturbation de la chaîne d'approvisionnement
• Tensions commerciales américaines-chinoises: 22% de complexité d'approvisionnement plus élevée
• Instabilité régionale du Moyen-Orient: 15% de défis de distribution potentiel

Changements de politique de santé du gouvernement

Pays	Impact de la réglementation des prix	Modifications de remboursement
États-Unis	-7,3% de réduction des revenus potentiels	Dispositions de négociation de l'assurance-maladie
Allemagne	-5,6% de pression de tarification	Prix ​​de référence stricte
Israël	-4,2% d'ajustement du marché	Préférence générique améliorée

Défis réglementaires sur les marchés clés

Paysage réglementaire du marché américain:

• Fréquence d'inspection de la FDA: trimestriel
• Risque de violation de la conformité: 12,5%
• Pénalité moyenne de non-conformité: 3,2 millions de dollars

Environnement réglementaire de l'UE:

• Processus d'approbation strict de l'EMA
• Coût de conformité du règlement des essais cliniques: 22 millions de dollars par an
• Complexité d'application de la protection des brevets:

Cadre réglementaire israélien:

• Incitations de fabrication locales
• Crédit d'impôt R&D: 6-12% de l'investissement
• Support du gouvernement en investissement pharmaceutique: 45 millions de dollars par an

Teva Pharmaceutical Industries Limited (TEVA) - Analyse du pilon: facteurs économiques

Restructuration financière continue pour réduire la dette et améliorer la rentabilité

Les efforts de restructuration financière de Teva en 2024 comprennent:

Métrique financière	Montant	Année
Réduction totale de la dette	5,2 milliards de dollars	2023
Dette nette	21,3 milliards de dollars	Q4 2023
Programme d'épargne-coût	3 milliards de dollars par an	2024

FLUCUATIONS DANS LES COMPRISES GLOBALES ET LA Dynamique du marché pharmaceutique

Analyse mondiale du marché pharmaceutique:

Segment de marché	Taux de croissance	Taille du marché
Marché pharmaceutique mondial	4.3%	1,8 billion de dollars
Segment pharmaceutique générique	3.9%	492 milliards de dollars

Risques de taux de change sur les marchés internationaux

Répartition de l'exposition aux devises:

Devise	Pourcentage d'exposition	Impact sur les revenus
Dollar américain	62%	8,7 milliards de dollars
Euro	18%	2,5 milliards de dollars
Autres devises	20%	2,8 milliards de dollars

Impact des ralentissements économiques sur les prix et la demande génériques des médicaments

Performance générique du marché des médicaments:

Métrique	Valeur	Année
Débulatoire moyen des prix des médicaments génériques	5.7%	2023
Volume générique du marché des médicaments	87% des ordonnances	2024
Revenus de médicaments génériques Teva	12,3 milliards de dollars	2023

Teva Pharmaceutical Industries Limited (TEVA) - Analyse du pilon: facteurs sociaux

Augmentation de la demande mondiale de médicaments génériques abordables

La taille du marché mondial des médicaments génériques était évaluée à 336,0 milliards de dollars en 2022, prévoyant une atteinte à 426,9 milliards de dollars d'ici 2030, avec un TCAC de 6,5%. Teva détient 11,4% de part de marché sur le marché mondial des produits pharmaceutiques génériques.

Région	Part de marché des médicaments génériques	Valeur marchande (2022)
Amérique du Nord	41.2%	138,4 milliards de dollars
Europe	29.5%	99,1 milliards de dollars
Asie-Pacifique	22.3%	75,0 milliards de dollars

La population vieillissante stimule la croissance du marché pharmaceutique

La population mondiale âgée de 65 ans et plus devrait atteindre 1,5 milliard d'ici 2050, ce qui augmente la demande pharmaceutique. La neurologie et les gammes de produits respiratoires de Teva ciblent spécifiquement les conditions liées à l'âge.

Groupe d'âge	Projection de population mondiale	Dépenses pharmaceutiques
65-74 ans	686 millions	420 milliards de dollars
75-84 ans	454 millions	590 milliards de dollars
85 ans et plus	239 millions	340 milliards de dollars

Conscience croissante des traitements de santé mentale

Global Mental Health Market estimé à 383,31 milliards de dollars en 2020, devrait atteindre 537,97 milliards de dollars d'ici 2030. TEVA génère environ 2,1 milliards de dollars par an à partir du portefeuille de médicaments psychiatriques.

Condition de santé mentale	Prévalence mondiale	Valeur marchande
Dépression	264 millions de patients	148,4 milliards de dollars
Troubles anxieux	284 millions de patients	126,5 milliards de dollars
Trouble bipolaire	46 millions de patients	57,2 milliards de dollars

Vers les approches de médecine personnalisée et de soins de santé centrés sur le patient

Marché de la médecine personnalisée prévoyant pour atteindre 796,8 milliards de dollars d'ici 2028, avec 6,8% de TCAC. Teva a investi 280 millions de dollars dans la recherche et le développement pour les thérapies ciblées en 2022.

Segment des soins de santé	Taux de croissance du marché	Projection d'investissement
Médecine de précision	7.2%	175,4 milliards de dollars
Recherche génomique	6.5%	92,3 milliards de dollars
Technologies de santé numérique	8.1%	509,2 milliards de dollars

Teva Pharmaceutical Industries Limited (TEVA) - Analyse du pilon: facteurs technologiques

Investir dans des plateformes de découverte de médicaments numériques et de médicaments dirigés par l'IA

En 2023, Teva a alloué 187 millions de dollars aux investissements de la recherche et du développement de l'IA. La plate-forme de découverte de médicaments dirigée par l'IA-AI a traité 42 673 composés moléculaires pour des applications thérapeutiques potentielles.

Catégorie d'investissement technologique	2023 Attribution du budget	Sortie de recherche
Découverte de médicaments IA	97 millions de dollars	12 456 candidats en médicament potentiel
Plateformes de santé numérique	90 millions de dollars	30 217 structures moléculaires analysées

Développement de systèmes avancés d'administration de médicaments et d'innovations de biotechnologie

Teva a investi 213 millions de dollars dans des technologies avancées de livraison de médicaments en 2023, ce qui a entraîné 17 nouvelles demandes de brevet pour des solutions innovantes de biotechnologie.

Technologie de livraison de médicaments	Investissement	Demandes de brevet
Systèmes de livraison de nanotechnologie	89 millions de dollars	7 brevets
Mécanismes de libération contrôlée	124 millions de dollars	10 brevets

Mise en œuvre des technologies de fabrication avancées

Teva a engagé 156 millions de dollars dans les technologies de fabrication avancées en 2023, améliorant 12 installations de production avec des systèmes de fabrication automatisés et de précision.

Technologie de fabrication	Investissement	Installations améliorées
Lignes de production automatisées	87 millions de dollars	8 installations
Systèmes de fabrication de précision	69 millions de dollars	4 installations

Amélioration de la cybersécurité et des infrastructures numériques pour la recherche et le développement

Teva a investi 64 millions de dollars dans les améliorations de la cybersécurité et des infrastructures numériques, mettant en œuvre des protocoles de protection avancée dans 23 centres de recherche mondiaux.

Investissement en cybersécurité	Budget	Centres de recherche protégés
Infrastructure de sécurité numérique	64 millions de dollars	23 centres de recherche mondiaux

Teva Pharmaceutical Industries Limited (TEVA) - Analyse du pilon: facteurs juridiques

Constructions de brevets en cours et défis de la propriété intellectuelle

Depuis 2024, Teva Pharmaceutical Industries Limited fait face à plusieurs cas de litige en matière de brevets:

Dossier de brevet	Frais juridiques estimés	Statut
Contestement de brevet médicament à la sclérose en plaques	127,5 millions de dollars	Litige en cours
Défi sur les brevets de médicament générique	93,2 millions de dollars	Résolution en attente
Copaxone Patent Litiging	412,6 millions de dollars	Partiellement résolu

Conformité aux réglementations pharmaceutiques internationales complexes

Coûts de conformité réglementaire pour Teva en 2024:

• Dépenses de conformité de la FDA: 45,3 millions de dollars
• Conformité de l'Agence européenne des médicaments: 38,7 millions de dollars
• Coûts de rapports réglementaires mondiaux: 22,6 millions de dollars

Règlements liés aux litiges juridiques liés aux opioïdes

Juridiction	Montant du règlement	Année
Règlement fédéral des États-Unis	4,35 milliards de dollars	2023-2024
Établissements d'opioïdes au niveau de l'État	1,2 milliard de dollars	2024

Navigation des exigences strictes de la conformité et de la déclaration des soins de santé

Métriques de conformité et de rapport pour Teva en 2024:

• Investissement du système de gestion de la conformité: 18,5 millions de dollars
• Personnel juridique et de conformité: 237 professionnels
• Dépenses de formation annuelle de conformité: 3,7 millions de dollars

Dépenses juridiques et conformes totales pour 2024: environ 6,14 milliards de dollars

Teva Pharmaceutical Industries Limited (TEVA) - Analyse du pilon: facteurs environnementaux

Mettre en œuvre des pratiques de fabrication durables

Teva s'est engagé à réduire les émissions de gaz à effet de serre de 50% d'ici 2030 par rapport aux niveaux de référence 2019. En 2022, la société a réalisé une réduction de 24,4% des émissions de la portée 1 et de la portée 2.

Métrique environnementale	2022 Performance	Cible 2030
Réduction des émissions de gaz à effet de serre	24.4%	50%
Réduction de la consommation d'eau	15.2%	30%
Taux de recyclage des déchets	62%	75%

Réduire l'empreinte carbone dans la production pharmaceutique

Teva a investi 45 millions de dollars dans des projets d'efficacité énergétique dans des installations de fabrication en 2022, entraînant des économies d'énergie annuelles de 76 000 MWh.

Initiatives d'efficacité énergétique	Investissement	Économies d'énergie annuelles
Mises à niveau des installations de fabrication	45 millions de dollars	76 000 MWh
Achat d'énergie renouvelable	12,3 millions de dollars	35% de l'énergie totale provenant de sources renouvelables

Développer des solutions d'emballage de drogues respectueuses de l'environnement

TEVA a réduit l'emballage en plastique de 22% entre les gammes de produits, dans le but d'utiliser un emballage 100% recyclable d'ici 2025.

Emballage des mesures de durabilité	Performance actuelle	Cible 2025
Réduction des emballages en plastique	22%	50%
Emballage recyclable	65%	100%

Investir dans des initiatives de technologies vertes et d'économie circulaire

TEVA a alloué 65 millions de dollars en 2022 pour les projets de recherche sur les technologies vertes et d'économie circulaire, en se concentrant sur des méthodes de production pharmaceutique durables.

Investissements technologiques verts	2022 allocation	Domaines de concentration
Recherche et développement	65 millions de dollars	Technologies de production durables
Initiatives de l'économie circulaire	18,7 millions de dollars	Réduction des déchets et récupération des ressources

Teva Pharmaceutical Industries Limited (TEVA) - PESTLE Analysis: Social factors

Sociological

The social dimension of Teva Pharmaceutical Industries Limited's (TEVA) operating environment is dominated by two major, and often conflicting, forces: the societal demand for affordable healthcare and the public reckoning over the opioid crisis. As a seasoned analyst, I see Teva's core value proposition-generic medicines-as a powerful, stabilizing social asset, but this is constantly weighed against the deep reputational damage from past legal challenges.

The economic impact of Teva's generic portfolio is staggering. For the most recent reporting period, Teva's generic medicines contributed to $39.7 billion in savings for healthcare systems across 22 countries. This is a concrete, massive benefit that directly addresses the rising cost of care for millions of patients and keeps national healthcare budgets solvent. That's the kind of number that changes policy conversations.

Teva has also made measurable progress on its commitment to increase access to medicine, a key social pillar. They exceeded their 2025 goal, launching a total of nine access-to-medicine programs, up from a target of eight. These aren't just paper programs; they translate directly into patient impact.

Here's the quick math on the Access-to-Medicine programs:

Metric	Amount/Value (2024 Report, pub. May 2025)	Social Impact
Total Access-to-Medicine Programs Launched	9	Exceeded the 2025 target of eight programs.
Total Doses Donated	~18 million doses	Directly provided free medication to vulnerable populations.
Value of Doses Donated	$23 million	Represents charitable contribution value to global health.
Patients Reached (Donated/Low-Cost)	187,000 patients	Directly benefited from access programs.
Health Systems Strengthening Programs	5 programs	Benefited ~56,000 individuals through capacity building.

Still, the opioid crisis remains a major social headwind. The nationwide opioid settlement, while a legal resolution, is fundamentally a public health response. As part of this, Teva is required to supply the anti-overdose drug naloxone, which is a critical tool in addressing the public health crisis. The settlement includes supplying up to $1.2 billion worth of Teva's generic version of naloxone to states and local governments over the settlement period. This provision forces the company to actively contribute to the solution for a crisis it helped fuel, directly mapping a legal obligation to a social imperative. It's a heavy, long-term social cost.

Internally, the focus on compliance is a direct response to past ethical failures. To rebuild trust, Teva has prioritized a culture of integrity. For the most recent reporting period, More than 99% of employees were retrained on compliance and ethics and Teva's Code of Conduct. This annual target achievement is crucial for mitigating future operational and legal risks, but honestly, it's the minimum expectation for a company of this size.

• Generic medicines saved $39.7 billion for healthcare systems.
• Opioid settlement includes supplying up to $1.2 billion of generic naloxone.
• Nine access-to-medicine programs launched, exceeding the 2025 goal.
• Over 99% of employees completed compliance and ethics training.

Teva Pharmaceutical Industries Limited (TEVA) - PESTLE Analysis: Technological factors

You're watching Teva Pharmaceutical Industries Limited transform from a generics giant into a biopharma leader, and the technology investments they are making right now are the engine for that shift. It's a calculated, dual-track strategy: inject next-generation tech like Artificial Intelligence (AI) into their core operations for efficiency, and push innovative, high-margin pipeline assets forward.

The clear takeaway is that Teva is using technology to drive a financial outcome-specifically, expanding its operating margin to a target of 30% by 2027. This isn't just about new drugs; it's about making the entire machine run better.

Launched Teva Rise in November 2025, an open innovation platform for AI and smart manufacturing

Teva is not trying to invent everything internally, which is smart. The company launched Teva Rise, a global open innovation platform, in November 2025 to co-create solutions with external startups and tech firms. This initiative is a direct play to accelerate the adoption of disruptive technologies, particularly in the areas of AI, Industry 4.0 (smart manufacturing), digital health, and biotech.

The platform is tackling seven real-world challenges across R&D, manufacturing, supply chain, and commercial functions. For instance, they are seeking AI-powered protocol designs for clinical trial simulations and predictive maintenance tools for their manufacturing assets. Teva plans to invest tens of millions of dollars into these global collaborations through the Rise platform. This is a defintely a faster way to get new tech into the business.

Pipeline includes 13 biosimilars, with five new launches planned by 2027

The technological sophistication required for biosimilars-biologic drugs highly similar to approved reference products-is a core competency for Teva. The company currently has a robust pipeline of 13 biosimilars. This is a critical area because it allows Teva to compete in the high-value biologics market but with a cost-advantaged product.

The strategy is clear: Teva is planning for five new launches of biosimilars by 2027. This wave of launches is projected to significantly boost their generics powerhouse segment, with the company aiming to achieve $800 million in biosimilar sales by 2027.

Biosimilar Pipeline Metric	2025 Fiscal Year Data	Strategic Goal
Total Biosimilars in Pipeline	13	Diversifying revenue base with complex products
New Launches Planned	5 (by 2027)	Accelerating growth in the generics segment
Targeted Biosimilar Sales	N/A (Targeting $800 million by 2027)	Compensating for gRevlimid revenue loss

Heavy R&D investment focuses on late-stage innovative assets like duvakitug (anti-TL1A)

The company's R&D spend is a clear indicator of its pivot toward innovative medicines. For the first three quarters of 2025 (Q1-Q3), Teva's net Research and Development expenses totaled $747 million ($247 million in Q1, $244 million in Q2, and $256 million in Q3). Management has guided that R&D expenses will exceed 6% of revenue for the full year 2025, which is a significant commitment to future growth.

The most important late-stage asset is duvakitug (anti-TL1A), a potential best-in-class treatment for inflammatory bowel disease (IBD). The Phase 3 program for duvakitug in ulcerative colitis and Crohn's disease was initiated in October 2025 in collaboration with Sanofi. This asset has a projected peak sales potential of between $2 billion and $5 billion, making it a future blockbuster and a cornerstone of Teva's innovative portfolio.

• Q1-Q3 2025 R&D spend: $747 million
• Duvakitug Phase 3 initiation: October 2025
• Duvakitug potential peak sales: $2 billion to $5 billion

Manufacturing transformation is ongoing to enhance efficiency and margins

Technology isn't just for the lab; it's also for the factory floor. Teva is executing a comprehensive manufacturing transformation as part of its 'Pivot to Growth' strategy. This is a crucial operational step to enhance competitiveness and margins, especially in the generics business.

The Teva Transformation programs are expected to generate approximately $700 million of net savings by 2027. For the 2025 fiscal year, the company is on track to deliver approximately $70 million in net savings from these programs, which is about 20% of the total targeted savings on a full-year run-rate basis. This efficiency gain is a key driver for the reaffirmed target of achieving a 30% operating margin by 2027. We've already seen the impact; the gross profit margin for the United States segment increased to 59.9% in the third quarter of 2025, up from 56.9% in the same quarter of 2024.

Next step: Review the R&D budget allocation to ensure the investment in duvakitug is prioritized, as that $2-5 billion asset is the biggest tech-driven opportunity.

Teva Pharmaceutical Industries Limited (TEVA) - PESTLE Analysis: Legal factors

Nationwide Opioid Litigation is Largely Resolved

You're looking for clarity on Teva Pharmaceutical Industries Limited's biggest legal overhang, and the good news is that the nationwide opioid litigation is defintely in the rearview mirror. Teva has successfully resolved its claims with all 50 U.S. states and more than 99% of the litigating subdivisions and special districts. This massive legal complexity is now largely a matter of financial management rather than courtroom drama.

The core of the resolution is a multi-year financial commitment. Teva's total nationwide opioid settlement is for up to $4.25 billion paid out over 13 years. This figure includes a mix of cash and product, specifically the overdose reversal drug naloxone. This structured, long-term payment plan helps smooth the financial impact on the company's balance sheet, which is crucial for a business focused on a 'Pivot to Growth' strategy.

Total Nationwide Opioid Settlement Details

Here's the quick math on what that $4.25 billion settlement actually entails for the company's 2025 fiscal year and beyond. The total value is split between cash payments and the provision of life-saving medicine. This breakdown is key for investors assessing the true cash flow impact.

Settlement Component	Maximum Value	Payment Period
Total Nationwide Opioid Settlement	Up to $4.25 billion	13 years
Cash Payments (to states, subdivisions, tribes)	Up to $3.05 billion	13 years
Generic Naloxone (Overdose Reversal Drug)	Up to $1.2 billion (Wholesale Acquisition Cost)	10 years
Cash in Lieu of Naloxone (Alternative Option)	$240 million (20% of WAC)	As elected by states

What this estimate hides is the ongoing, separate settlements. For example, Teva also agreed to pay up to $126 million in cash over 18 years to U.S. hospitals to settle claims that its opioid marketing increased their operating costs. Plus, they agreed to supply up to $49 million in generic naloxone to these hospitals over seven years. It shows the legal clean-up is comprehensive, but still a significant financial drain.

Ongoing Risk of Intellectual Property and Regulatory Compliance

While the opioid cloud is lifting, Teva, as a global generics and specialty drug powerhouse, faces constant legal pressure from intellectual property (IP) infringement claims and complex global regulatory compliance. This is simply the cost of doing business in pharma.

The biggest near-term risk is the antitrust scrutiny over patent listings. In October 2025, Teva agreed to pay $35 million to settle a class-action antitrust lawsuit alleging improper listing of patents for its ProAir HFA inhaler in the FDA's Orange Book. This followed a December 2024 US Court of Appeals for the Federal Circuit ruling that five of the inhaler's patents were improperly listed because they covered the device, not the active ingredient. Losing this legal shield removes the automatic 30-month stay on generic competition, which is a major strategic blow.

Also, the European Commission fined Teva €462.6 million (approximately $503 million) in October 2024 for misusing the patent system to delay competition for its multiple sclerosis drug Copaxone. This shows global regulators are serious about competition.

The company's own Q2 2025 risk analysis highlights that 'Legal & Regulatory' matters account for 31% of the total risks. This isn't just about lawsuits; it's about navigating a maze of global rules.

• Comply with FDA, EMA, and other regulators on manufacturing and labeling.
• Adhere to new U.S. state pricing laws that impose penalties for high costs.
• Manage global anti-bribery, competition, and economic sanctions laws.

Your clear action is to monitor the cash flow impact of the opioid settlements and, more importantly, track the financial fallout from the IP/antitrust challenges, as these directly impact the time-to-market for generics and the profitability of branded drugs.

Teva Pharmaceutical Industries Limited (TEVA) - PESTLE Analysis: Environmental factors

Surpassed the 2025 goal, achieving a 29% reduction in Scope 1 and 2 GHG emissions from 2019 levels.

You need to know where a company is putting its capital to work on environmental, social, and governance (ESG) issues, and Teva Pharmaceutical Industries Limited is showing strong execution on climate. They have already surpassed their near-term goal for operational emissions. The original target was a 25% reduction in absolute Scope 1 and Scope 2 Greenhouse Gas (GHG) emissions-the direct emissions from their owned or controlled sources-by the end of 2025, but they hit this two years early. The latest 2025 fiscal year data confirms they achieved a 29% reduction from the 2019 baseline.

This early win is a strong signal of management focus and operational efficiency. Here's the quick math: they beat the target by 4 percentage points, which defintely lowers their climate-related financial risk profile. They also reduced their Scope 3 emissions (indirect emissions from the value chain) by 12% against a 2020 baseline, tracking toward a 25% reduction goal by 2030.

New long-term target: 100% renewable electricity across all sites by 2035.

The company is mapping out its long-term decarbonization strategy with an aggressive renewable energy goal. Teva has committed to achieving 100% use of renewable electricity across all its global sites by 2035. This is a critical move to future-proof their manufacturing footprint against rising energy costs and carbon taxes. As of their most recent reporting, they were already sourcing 43% of their electricity from renewable sources, showing solid progress toward the 2035 deadline.

This commitment is part of a broader, more ambitious plan to reach net-zero emissions across their entire operations and value chain by 2045. That's a clear action for investors to track over the next two decades.

Issued $7.5 billion in sustainability-linked bonds, the largest in the pharma sector.

A major financial opportunity for Teva is its use of sustainable finance instruments. They have issued a total of $7.5 billion in sustainability-linked bonds (SLBs), which is the largest issuance of its kind in the pharmaceutical sector. This debt instrument is a powerful tool because the interest rate paid on the bonds is tied directly to the company's achievement of its ESG targets.

The total is composed of a $5 billion initial bond in 2021 and a second series valued at $2.49 billion in 2023. The key performance indicators (KPIs) for these bonds include the Scope 1 and 2 GHG emissions reduction and an increase in access to essential medicines. Because they surpassed the GHG reduction target, it's a positive signal for the bond's performance and the cost of capital.

Metric	Target	2025 Fiscal Year Status (as of May 2025 Report)	Financial Linkage
Scope 1 & 2 GHG Emissions Reduction (vs. 2019)	25% by 2025	Achieved 29% reduction (Surpassed target)	KPI for $7.5 billion Sustainability-Linked Bonds
Renewable Electricity Use	100% by 2035	43% used in 2023 (Tracking toward goal)	Part of Net-Zero by 2045 strategy
Antibiotic Safe Discharge Levels	80% of applicable sites	73% of applicable sites achieved safe discharge levels	Reduces Pharmaceuticals in the Environment (PIE) risk

73% of applicable sites achieved safe discharge levels of antibiotics, reducing pollution.

The pharmaceutical industry faces unique environmental challenges, particularly around the discharge of active pharmaceutical ingredients (APIs), like antibiotics, into waterways. Teva is actively managing this risk, which is crucial for public health and regulatory compliance. They have a commitment to minimize antimicrobial discharges to combat Antimicrobial Resistance (AMR).

As of the 2025 fiscal year reporting, 73% of their applicable manufacturing sites achieved safe discharge levels of antibiotics. While this is a high level of performance, it indicates there is still a gap to close against their original target of 80% of applicable sites achieving safe discharge levels (Risk Quotient <1). This is a near-term risk to monitor, as failure to reach the target could trigger regulatory scrutiny or reputational damage, but their current performance is a strong mitigation against environmental pollution.

• Achieved safe discharge at 73% of applicable sites.
• Minimizes environmental pollution from active pharmaceutical ingredients.
• Helps mitigate the global crisis of Antimicrobial Resistance (AMR).

Finance: draft 13-week cash view by Friday.